Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS) - Scorecard - MDSpire
Advertisement
Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS)
Clinical Scorecard: Approaches to Treating Inflammatory Ocular Surface Disease and Chronic Epithelial Defects within the UK National Health Service (NHS)
At a Glance
Category
Detail
Condition
Key Mechanisms
Disruptions to the epithelial barrier and basement membrane due to trauma, infection, surgery, or systemic disease. [1]
Target Population
Care Setting
UK National Health Service (NHS) hospitals.
Key Highlights
PED defined by failure of corneal re-epithelialisation beyond 10–14 days. [2, 3]
Management requires a multifactorial treatment approach. [4]
Common treatments include lubrication, bandage contact lenses, and surgical options. [1, 4, 5, 9,10,11,12,13,14,15,16,17]
Chronic PEDs generate high cumulative burden due to prolonged healing and frequent monitoring. [18, 19]
Lack of real-world data on treatment burden and costs within the NHS.
Guideline-Based Recommendations
Diagnosis
PED diagnosed by failure to complete epithelialisation 10–14 days after onset. [2, 20]
Management
Stepwise treatment escalation starting with intensive lubrication. [8]
Monitoring & Follow-up
Frequent follow-up required for chronic PED management.
Risks
Complications include corneal melting, scarring, secondary infection, and perforation. [1]
Patient & Prescribing Data
Patients diagnosed with ocular surface disease in acute and chronic phases.
Treatment pathways include conventional topical therapies and surgical interventions.
Clinical Best Practices
Utilize a multifactorial approach to address underlying causes of PED. [4]
Monitor patients closely for complications and treatment efficacy.
Document treatment pathways and outcomes for better resource allocation.
